Unigen Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.05 M
as on 21-12-2024
- Paid Up Capital ₹ 1.04 M
as on 21-12-2024
- Company Age 12 Year, 15 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 1244.45%
(FY 2020)
- Profit 254.17%
(FY 2020)
- Ebitda -72.06%
(FY 2020)
- Net Worth 55.70%
(FY 2020)
- Total Assets -34.94%
(FY 2020)
About Unigen Life Sciences
The Corporate was formerly known as Unigen Life Sciences India Private Limited. The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.05 M and a paid-up capital of Rs 1.04 M, as per Ministry of Corporate Affairs (MCA) records.
Hrangdanglien and Jacob Fiedler serve as directors at the Company.
- CIN/LLPIN
U24297MH2013FTC239278
- Company No.
239278
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
04 Jan 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Unigen Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hrangdanglien  | Director | 22-May-2019 | Current |
Jacob Fiedler  | Director | 04-Jan-2013 | Current |
Financial Performance of Unigen Life Sciences.
Unigen Life Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 1244.45% increase. The company also saw a substantial improvement in profitability, with a 254.17% increase in profit. The company's net worth Soared by an impressive increase of 55.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unigen Life Sciences?
In 2017, Unigen Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zenzi Pharmaceutical Industries Private LimitedActive 19 years 1 monthHrangdanglien and Jacob Fiedler are mutual person
- Alpha-Pharma Healthcare Private LimitedActive 11 years 5 days
Hrangdanglien and Jacob Fiedler are mutual person
Meghdoot Chemicals LimitedActive 54 years 4 monthsHrangdanglien and Jacob Fiedler are mutual person
- Coin Pharmaceuticals Private LimitedActive 12 years 7 months
Hrangdanglien and Jacob Fiedler are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unigen Life Sciences?
Unlock and access historical data on people associated with Unigen Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unigen Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unigen Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
